KLRC1 and neoplasm: Thus, deploying anti-NKG2A mAbs may promote the activity (and memory formation) of highly specific anti-tumour cytotoxic T cells, making NKG2A an ideal candidate to target in combination with vaccines that induce prolonged TCR stimulation.